Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 129.73B P/E 18.00 EPS this Y -92.70% Ern Qtrly Grth -
Income -6.15B Forward P/E 8.64 EPS next Y 1,239.20% 50D Avg Chg -4.00%
Sales 45.53B PEG -16.94 EPS past 5Y 11.28% 200D Avg Chg -12.00%
Dividend 4.00% Price/Book 4.03 EPS next 5Y -5.24% 52W High Chg -24.00%
Recommedations 2.70 Quick Ratio 0.92 Shares Outstanding 2.03B 52W Low Chg 3.00%
Insider Own 0.11% ROA 5.39% Shares Float 2.02B Beta 0.44
Inst Own 79.10% ROE -25.33% Shares Shorted/Prior 32.06M/30.29M Price 61.75
Gross Margin 76.03% Profit Margin -13.50% Avg. Volume 8,754,443 Target Price 49.29
Oper. Margin 19.25% Earnings Date Jul 26 Volume 9,548,659 Change 0.36%
About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company News
12:04 AM Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
07/26/24 Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win
07/26/24 These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More
07/26/24 Why Bristol Myers Squibb Jumped Nearly 10% on Friday
07/26/24 Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
07/26/24 Newell Brands, 3M rise; Saia, DexCom fall, Friday, 7/26/2024
07/26/24 Top Midday Stories: Fed's Preferred Inflation Reading Up in June; 3M's Adjusted Earnings Gain; DexCom Cuts 2024 Revenue Guidance; Bristol-Myers Squibb's Higher Results; WesBanco, Premier Financial to Merge
07/26/24 Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter
07/26/24 Bristol Myers Stock Rises Sharply. A Sales Jump for Eliquis Boosts Earnings.
07/26/24 PCE/Core PCE Inflation In Line With Estimates in June
07/26/24 Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
07/26/24 Pre-Markets Swell, PCE Behaves, Several Q2 Beats
07/26/24 Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
07/26/24 Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
07/26/24 Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
07/26/24 Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
07/26/24 Bristol Myers’ beat completes strong week of pharma earnings
07/26/24 Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
07/26/24 Bristol Myers: Q2 Earnings Snapshot
07/26/24 Bristol Myers second-quarter results beat expectations, helped by new drugs
BMY Chatroom

User Image stockpivot Posted - 2 hours ago

$BMY Will be Closing Position on Monday with 16.64% Profit

User Image victorcastro Posted - 2 hours ago

$MMM $BAH $NWL $CHTR $BMY

User Image JackDarwin Posted - 2 hours ago

$BMY Bullish Gap Up Formed.

User Image FIREGirl420 Posted - 4 hours ago

$BMY $AMLP $PFE $T $VZ This info has been golden this year 🧐👇

User Image FIREGirl420 Posted - 4 hours ago

$PFE $GILD $BMY $ABBV What a week

User Image Pitbowl Posted - 4 hours ago

$BDX $MRMD - Cannabis Icecream $BMY $CERN $CI https://www.youtube.com/shorts/KsYYrvMNybc

User Image Thesis_Alexander Posted - 4 hours ago

$BMY The evidently unqualified financial analysts, who were reducing their price targets, prior to earnings will be making upward adjustments now. "Cantor Fitzgerald Raises Price Target on Bristol-Myers Squibb to $50 From $45" https://www.tradingview.com/news/mtnewswires.com:20240726:A3187864:0/

User Image BraydenHoare Posted - 5 hours ago

$BMY $IBIT Join our WhatsApp group for day Traders and stay informed about market trends and opportunities! Whats-app group Link Here;;. https://chat.whatsapp.com/Be2G5nWf9NVCcSKWiN4Ue9

User Image Spicy_Trade Posted - 6 hours ago

$BMY stock analysis https://youtu.be/IzGK0tSSdBc?si=uct_VW2noJNnz4O8

User Image Pitbowl Posted - 6 hours ago

$MSFT $IBIT $BMY $SUKU.X $MRMD Cannabis Icecream... https://www.bettyseddies.com/categories/ice-cream #MRMD

User Image Ro_Patel Posted - 6 hours ago

Today's option volume of 48.8M contracts was in line with recent average levels, w/ calls leading puts 11 to 9. ETF & single stock products saw relatively heavy volume, while index flow was moderate. Today's most active sectors included Telecommunications, Health Care, & Industrials, while Consumer Cyclicals & Utilities were relatively light. Among the 500 most liquid single stocks, 30day IV was higher for 138 & lower for 300. Unusual total option volume was observed in $MMM $BMY $ASTS $DXCM & $GILD

User Image TIGHTSTOPLOSS Posted - 6 hours ago

$BMY on the dot

User Image mikesterz7 Posted - 7 hours ago

$BMY PT 60

User Image DividendPower Posted - 7 hours ago

The List of Dividend Contenders 2024 - Updated 07/26/24 https://www.dividendpower.org/list-dividend-contenders-2024/ $AAPL $NEP $BMY $ZTS $DLB

User Image Ycapital Posted - 7 hours ago

$BMY adding

User Image StockInvest_us Posted - 7 hours ago

Today $BMY shows HOLD signal (TA) for short term. Technical analysis source: https://stockinvest.us/l/Z2sHOaGIhm

User Image Barbann Posted - 7 hours ago

$BMY 60 Monday.

User Image Article_AI Posted - 8 hours ago

$BMY Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thinner Eliquis and a portfolio of drugs it expects to help it deliver long-term growth. https://www.stck.pro/news/BMY/86077843/

User Image Glennifer Posted - 8 hours ago

$BMY hey wyd- wonderful!!

User Image Clargy Posted - 8 hours ago

$BMY If anyone ever tells you that technical analysis is BS, have them take a look at this chart haha

User Image RookyMoves Posted - 8 hours ago

$BMY that was the bottom indeed.

User Image Cashflow62 Posted - 8 hours ago

$BMY

User Image KISScharts Posted - 8 hours ago

$BMY y’all weird. If you wanted it this bad, you should have bought in low 40s. Now it is in extreme overbought conditions. Makes my job harder because crazy coming in.

User Image stanfrombrooklyn Posted - 8 hours ago

$BMY sold at $50 why? Because I bought at 41. While buying ATM put leaps and selling OTM calls. Not a bad 4x trade w limited risk. BUT F! this is about to fly! GLTA who are holding beyond $50

User Image abenscher Posted - 8 hours ago

$WINT $MMM $BMY $ASTS So you took a trade overnight and it isn’t working out. Now what? Here’s what to do. https://youtu.be/jjJ7li56NEU

User Image MF__DOOM Posted - 9 hours ago

$BMY decent AH volume

User Image clinician55 Posted - 9 hours ago

$BLUE Sweet ride on my sizable $BMY position. $BLUE equally undervalued, but equally sized position.

User Image Avj7 Posted - 9 hours ago

$BMY So glad I averaged down!!!

User Image GuerillaStockTrading Posted - 9 hours ago

Bristol-Myers Squibb’s stock soars! 🚀 With an earnings beat and booming new drug sales, it's time to pay attention! 📈 $BMY #InvestSmart #PharmaSuccess #BMY http://dlvr.it/TB6jHr

User Image SniperPro Posted - 9 hours ago

$LXRX $BMY $NVS My bet is between BMY and NVS for INPEFA acquisition, both need a new drug to replace/improve their hf pipeline... We'll see if I get it right... DD pays off, if you go deep down the rabbit hole.... To be continue... $PFE $MRK ???

Analyst Ratings
Deutsche Bank Hold Jul 23, 24
Cantor Fitzgerald Neutral Jul 22, 24
Barclays Equal-Weight Jul 10, 24
BMO Capital Market Perform Apr 26, 24
Barclays Equal-Weight Apr 26, 24
Wells Fargo Equal-Weight Apr 18, 24
Wells Fargo Equal-Weight Feb 6, 24
Redburn Atlantic Neutral Feb 6, 24
B of A Securities Neutral Jan 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Dec 05 Buy 49.78 2,000 99,560 82,672 12/07/23
BOERNER CHRISTOPHER S. Chief Executive Offi.. Chief Executive Officer Nov 28 Buy 48.86 3,071 150,049 79,384 11/30/23
Samuels Theodore R. II Director Director Nov 20 Buy 49.81 8,500 423,385 35,500 11/21/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Aug 24 Sell 61.25 17,986 1,101,642 27,868 08/28/23
Plenge Robert M EVP, Chief Research.. EVP, Chief Research Officer Aug 03 Sell 61.14 732 44,754 6,584 08/07/23
VESSEY RUPERT EVP & President, Res.. EVP & President, Research May 03 Sell 67.06 50,385 3,378,818 47,751 05/04/23
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 06 Sell 74.65 240,000 17,916,000 236,104 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Feb 06 Sell 74.69 11,183 835,258 23,043 02/08/23
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Nov 09 Sell 80.45 16,250 1,307,312 34,226 11/14/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Option 54.85 52,604 2,885,329 102,989 11/09/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 07 Sell 78.88 45,910 3,621,381 57,079 11/09/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Sell 71.32 133,951 9,553,385 119,786 09/15/22
Elkins David V EVP, Chief Financial.. EVP, Chief Financial Officer Sep 13 Option 48.49 123,277 5,977,702 223,737 09/15/22
Powell Ann EVP, Chief Human Res.. EVP, Chief Human Resources Sep 14 Sell 70.75 25,000 1,768,750 50,476 09/15/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Jun 13 Sell 74.04 30,000 2,221,200 551,104 06/14/22
LEUNG SANDRA EVP, General Counsel EVP, General Counsel Jun 06 Sell 74.89 65,000 4,867,850 308,627 06/07/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Mar 21 Sell 71.52 25,000 1,788,000 581,524 03/23/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Option 53.64 47,305 2,537,440 93,613 03/18/22
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Mar 16 Sell 69.25 74,559 5,163,211 50,385 03/18/22
Santiago Karen Murphy SVP & Controller SVP & Controller Mar 14 Sell 69.195 6,577 455,096 16,704 03/16/22
BOERNER CHRISTOPHER S. EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 14 Sell 69.197 29,532 2,043,526 41,966 03/16/22
Caforio Giovanni Board Chair and CEO Board Chair and CEO Feb 24 Sell 67 30,000 2,010,000 453,455 02/28/22
von Autenried Paul EVP, Chief Informati.. EVP, Chief Information Officer Nov 22 Sell 57.19 51,134 2,924,353 63,536 11/24/21
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20